Lifeline Therapeutics’ Director of Science is the Co-discoverer of Superoxide Dismutase (SOD)
Dr. Joe McCord, the preeminent SOD scientist is part of the Lifeline management team
In 1969, Dr. Joe McCord, together with Irwin Fridovich, discovered SOD, spawning an avalanche of scientific research and affirmation. For this monumental achievement, he and Fridovich were awarded the prestigious Elliot Cresson Medal for "for their seminal work, singly and together, of discovering and elucidating the biology of free radical reactions and their enzymatic controls in living organisms, as well as the pathology of free radical diseases." Previous recipients of the award, founded in 1848, have included such notable scientists and inventors as Alexander Graham Bell, Orville Wright, Henry Ford, Wernher von Braun, Pierre and Marie Curie, and Andrei Sakharov. Dr. McCord therefore stands in distinguished company for greatly impacting lives for generations to come.
Dr. McCord's additional awards are too numerous to list, but they include a Lifetime Achievement Award from the Oxygen Society for outstanding contributions to the field of free radical biology and medicine. Dr. McCord has served as the President of the International Society of Antioxidants in Nutrition and Health (ISANH). He was also the Chairman of the 2nd International Conference on Superoxide Dismutases: Recent Advances and Clinical Applications, which was held at the Institute Pasteur in Paris. In addition, Dr. McCord has been published in many scientific journals including the greatly-respected New England Journal of Medicine.
Dr. McCord served as an Executive Editor for the Archives of Biochemistry and Biophysics; Serves on the Editorial Board for the Journal of Biochemistry, and the Editorial Board of Inflammation Research Interests: The Chemistry and Pathophysiology of Superoxide and Related Free Radicals, especially with regard to oxidant/antioxidant balance in such diseases as AIDS, Down's Syndrome, cancer, and diabetes.
Dr. McCord currently serves as the Head for the Division of Biochemistry and Molecular Biology at the Webb-Waring Institute for Cancer, Aging, and Antioxidant Research. As the discoverer of SOD, paramount SOD researcher, and author of numerous studies and articles on SOD, Dr. McCord is the most highly-regarded expert in the field of Superoxide Dismutases.
Dr. Joe McCord Publications (short list)….
Some "Citation Classics":
• J.M. McCord and I. Fridovich, Superoxide Dismutase: an Enzymic Function for Erythrocuprein (Hemocuprein), J. Biol. Chem. 244: 6049-6055 (1969).
• J.M. McCord, Free Radicals and Inflammation: Protection of Synovial Fluid by Superoxide Dismutase, Science 185:529-531 (1974).
• J.M. McCord, Oxygen-Derived Free Radicals in Post-Ischemic Tissue Injury, New Eng. J. Med. 312:159-163 (1985).
Some Recent Publications:
• M.P. Look, K. Krämer, J.K. Rockstroh, J.M. McCord and L. Packer, High-dose nutraceuticals in human immunodeficiency virus-disease. An understudied option? Curr. Topics Nutraceut.Res. 1: 1-16 (2003).
• W.H. Cerwinka, C.F. Krieglstein, C.R. Ross, J.M. McCord and D.N. Granger, Superoxide mediates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am. J. Physiol. Heart Circ. Physiol. 284: H535- H541 (2003).
• I.N. Hines, J.M. Hoffman, H. Scheerens, B.J. Day, H. Harada, K.P. Pavlick, S. Bharwani, R. Wolf, B. Gao, S.C. Flores, J.M. McCord and M.B. Grisham, Regulation of post-ischemic liver injury following different durations of ischemia, Am. J. Physiol.Gastrointest Liver Physiol. 284:G536-G545 (2003).
• B. Gao, S.C. Flores, J.A. Leff, S.K. Bose, and J.M. McCord, Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3, Am. J. Physiol. Lung Cell Mol. Physiol. 284: L917-L925 (2003).
• E.S.M. Ng, D. Jourd'heuil, J.M. McCord, D. Hernandez, M. Yasui, D. Knight, and P. Kubes, Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion Circ. Res. 94:559-565 (2004).
• H. Harada, I. Hines, S. Flores, B. Gao, J. McCord, H. Scheerens, and M. Grisham, Role of NADPH oxidase-derived superoxide in reduced size liver ischemia and reperfusion injury, Arch. Biochem. Biophys. 423: 103-108 (2004).
• C.S. Bonder, D. Knight, D. Hernandez-Saavedra, J.M. McCord and P. Kubes, Chimeric SOD2/3 inhibits at the endothelial-neutrophil interface to limit vascular dysfunction in ischemia/reperfusion, Am. J. Physiol. Gastrointest Liver Physiol. In press (2004).
About Superoxide Dismutase…
The first line of defense that the body has against superoxide free radicals is the enzyme known as Superoxide Dismutase (SOD) which is existent in three forms and considered the body's most effective antioxidant.
The importance of SOD is so paramount for the protection of our cells that animals cannot live without it. In brief, SOD keeps oxygen under control. SOD activity has been determined to be directly correlated to aging and lifespan determination.
Medquest reports that "SOD may in fact be the most powerful life-extending discovery of our time." However, SOD production declines with age, allowing for a multitude of age-related conditions to set in. SOD must therefore be enhanced, starting in our mid-to-late twenties, in order to combat the ravages of free radicals. SOD must also be increased in tandem with Catalase (CAT) and Glutathione Peroxidase (GPX) as part of a coordinated defense and repair system. SOD, CAT and GPX enhancement is the sole mission of Lifeline Therapeutics, Inc.
About Lifeline Therapeutics Corp…
Lifeline is a privately held, Denver-based company formed to manufacture, market and distribute nutraceutical supplements that promote "Healthy Life Expectancy." Lifeline is presently focusing exclusively on unique antioxidant therapies under its Protandim brand. The therapies center on the body's primary defense mechanism against oxidative stress - the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX). Discussions have commenced regarding license agreements and other collaborative arrangements in order to aggressively place its Protandim product candidates into the global marketplace.
AI
